Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | PHGDH | O43175 | 1/20 | 0.36 |
| ▸ | THRA | P10827 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | USP5 | P45974 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21027022 | 0.74 | SYK (0.39) | PTGDR2KDM4EUSP5KMT2A | |
| SCHEMBL21027516 | 0.74 | SYK (0.39) | PTGDR2KDM4EUSP5KMT2A | |
| SCHEMBL21027528 | 0.74 | SYK (0.39) | PTGDR2KDM4EUSP5KMT2A | |
| SCHEMBL11397353 | 0.66 | ALDH1A1 (0.41) | PTGDR2CSNK2A2CSNK2BCSNK2A1KDM4E | |
| SCHEMBL11826429 | 0.66 | KDM4E (0.51) | KDM4EUSP5KMT2A | |
| SCHEMBL150034 | 0.65 | KMT2A (0.53) | KDM4EUSP5KMT2A | |
| SCHEMBL18258624 | 0.65 | KMT2A (0.53) | KDM4EUSP5KMT2A | |
| SCHEMBL21027730 | 0.65 | P2RX4 (0.50) | KDM4EPTGS2USP5KMT2A | |
| SCHEMBL14232159 | 0.64 | PTGDR2 (0.44) | PTGDR2KDM4EPTGS2 | |
| SCHEMBL15486713 | 0.64 | DNMT1 (0.45) | PTGDR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256130-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | GOODMAN KRISTA B | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256130-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | UTS2R, AVPR2, VIPR2 | NOTUM 3115/4885PTGDR2 90/4885PHGDH 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.